CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be avail ...

FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March. TD Cowen's 46th Annual Health Care ConferenceFormat: Fireside ChatDate and Time: Monday, March 2, 2026 at 3:50 p.m. ET Location: Boston, MA Leerink Global Healthcare Conference Format: Fireside ChatDate and Time: Monday, M ...

CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously ...

Core Insights - Hematology Oncology of Indiana (HOI) has welcomed Dr. Amy Braden, a Board-certified medical oncologist and hematologist, to its physician team, enhancing its capacity to provide patient-centered cancer care [1][4] Company Overview - Hematology Oncology of Indiana is a community-based practice that offers comprehensive cancer care services across six locations in Indiana, including metropolitan Indianapolis and surrounding areas [3][8] - The practice focuses on delivering high-quality cancer services, including specialty infusion services, pathology, pharmacy, clinical trials, and BiTE therapy, emphasizing a holistic approach to patient treatment [3] Professional Background - Dr. Braden has over 10 years of experience in patient care, having completed her Doctorate of Osteopathic Medicine at Nova Southeastern University and her residency and fellowship at reputable institutions [2] - Her addition to the team is expected to enhance the quality of care provided to patients, aligning with HOI's commitment to personalized treatment [3][4] Network Expansion - American Oncology Network (AON), which HOI is a part of, is rapidly expanding, representing over 300 providers across 20 states since its founding in 2018 [7] - AON aims to improve patient outcomes through innovative healthcare solutions and a physician-led model that promotes value-based care [7]

Market Overview - The trading day is concluding with a modest rally in major indices, with the Dow Jones Industrial Average up 300 points (0.6%), the S&P 500 up 35 points (0.5%), and the Nasdaq up 0.4% [7][8]. - The upcoming week is anticipated to be significant for the market, particularly with earnings reports from major tech companies like Meta, Microsoft, Apple, and Tesla [3][6]. Earnings Expectations - Analysts expect a broadening of the earnings picture, indicating that not only big tech names will be in focus but also other companies that may show meaningful earnings and revenue growth [6][7]. - The sentiment around the Federal Reserve's upcoming meeting and Fed Chair Jerome Powell's comments will also play a crucial role in market momentum [5][6]. Sector Performance - Communication services led the sector performance, driven by companies like Alphabet and Meta, while consumer discretionary and consumer staples sectors saw declines [9][10]. - Rare earth companies experienced significant movement, particularly USA Rare Earths, which rose nearly 8% following a non-binding agreement with the U.S. Commerce Department for $1.6 billion in funding to boost domestic production [11][13]. Company-Specific News - Nvidia announced an additional $2 billion investment in a cloud computing firm, contributing to a 5.7% increase in its stock price, which is up over 40% year-to-date [14]. - GameStop shares rose approximately 4.5% after Michael Barr expressed confidence in the company's future and his recent purchases of shares [15]. - Booz Allen Hamilton's shares fell over 8% after the U.S. Treasury canceled $21 million in contracts due to data protection failures [17]. - The Trade Desk's stock declined more than 7% following the termination of its CFO, Alex Kail [18]. - Revolution Medicines saw a significant drop of 17% after reports that Merck ended acquisition talks, raising concerns about valuation discipline [20]. Economic Impact - A notable decline in bookings (35%) at a Vermont ski resort was reported, attributed to strained U.S.-Canada relations affecting Canadian customers [28][30]. - The economic ramifications of these relations are highlighted as a microcosm of broader macroeconomic issues impacting both sides of the border [31].

Core Viewpoint - Genesis Cancer and Blood Institute (GCBI) expands its services by adding endocrinology care through the recruitment of Dr. Daryl Burrows and APRN Natalie Brown, enhancing patient care in a community-based setting [1][2][4]. Group 1: Service Expansion - The addition of endocrinology services allows patients to receive specialized care alongside their oncology treatment, which was previously unavailable at GCBI [2][5]. - Dr. Burrows and Natalie Brown are now part of a comprehensive care team that includes 11 medical oncologists and other advanced practice providers across 11 locations in Arkansas [5][6]. Group 2: Professional Background - Dr. Daryl Burrows earned his medical degree from the University of Arkansas for Medical Sciences and completed a fellowship in diabetes, endocrinology, and metabolism [3]. - Natalie Brown holds a Master of Science in Nursing from the University of Central Arkansas and has nearly 15 years of nursing experience, including 10 years in endocrinology [4]. Group 3: Commitment to Patient Care - The introduction of endocrinology services reflects GCBI's commitment to providing comprehensive, patient-centered care close to home [4][6]. - AON's mission to deliver high-quality, patient-first community care is supported by the addition of Burrows and Brown to the care team [7].

Group 1 - Genmab A/S is recognized as one of the top oncology stocks to buy, with Deutsche Bank raising its price target for GMAB to DKK 2,400 from DKK 2,000 and maintaining a Buy rating, indicating strong analyst optimism regarding the company's late-stage oncology pipeline [1][3] - The company has partnered with AI research firm Anthropic to enhance its R&D capabilities through the use of agentic AI powered by Claude models, aiming for a more scalable and effective R&D process while maintaining human oversight [2] - Genmab specializes in developing innovative antibody-based therapies for cancer treatment, with its late-stage pipeline featuring promising programs such as Rina-S and Epkinly [3]

Market Overview - U.S. markets ended the week with mixed results, as major benchmarks showed modest declines while small-cap stocks outperformed, with the Russell 2000 achieving record highs [2][4] - The Dow Jones Industrial Average and S&P 500 experienced slight decreases, while the Nasdaq also slipped, indicating an uneven market rally [2][3] Sector Performance - Semiconductor and AI-related technology stocks, particularly Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC), contributed to market stability earlier in the week, with TSMC reporting a 35% increase in net profit, driven by strong AI demand [3][6] - Bank earnings from Goldman Sachs and Morgan Stanley supported trading, despite rising Treasury yields and modest increases in oil prices [3] Small-Cap Stocks - The Russell 2000's performance marked a significant outperformance streak against the S&P 500, a trend not seen since 2008, bolstered by strong economic indicators such as low initial jobless claims [4] Notable Stock Movements - Venus Concept Inc. saw its stock surge over 500% after Madryn Asset Management acquired a 91% stake, leading to increased trading volume and investor interest despite recent revenue declines [8] - J.B. Hunt Transport Services Inc. reported mixed Q4 results, with revenue of approximately $3.097 billion slightly missing expectations, while earnings per share of $1.90 exceeded forecasts [11] - Plus Therapeutics Inc. faced a stock decline after pricing a public offering to raise $15 million at a discounted price, impacting investor sentiment [12] Analyst Insights - Rocket Lab USA, Inc. received a rare downgrade from Loop Capital, citing valuation concerns and near-term execution risks, which led to a decline in its stock price [10]

Core Insights - Aktis Oncology, Inc. is a clinical-stage oncology company focused on developing innovative cancer treatments, aiming to significantly impact the biotech sector [1] - The company recently completed its initial public offering (IPO), which is the first sizable offering of 2026, highlighting its growth potential and strategic positioning within the biotech industry [3] IPO Details - Aktis Oncology's IPO involved offering 17.65 million shares at $18 each, with an upsized offering that included an additional 2.65 million shares purchased by underwriters, bringing total gross proceeds to approximately $365.4 million [2] - The shares began trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026 [2] Market Performance - As of the latest trading, AKTS is priced at $20.56, reflecting a slight decrease of 1.20% or $0.25, with a daily trading range between $19.69 and $21.43 [3] - Over the past year, the stock has seen a high of $29.16 and a low of $19.02, with a current market capitalization of approximately $1.08 billion and a trading volume of 234,338 shares on the NASDAQ exchange [3]

Core Viewpoint - RenovoRx is making significant progress in its commercial and clinical programs, particularly with its FDA-cleared drug-delivery device, RenovoCath, and its ongoing clinical trials for targeted oncology therapies [1][3]. Commercial Progress - The demand for RenovoCath as a standalone targeted drug-delivery device is increasing, with adoption growing among both new and returning customers, including leading cancer centers [2][10]. - In December 2024, RenovoRx received its first commercial purchase orders for RenovoCath devices, with several customers initiating repeat orders [10]. Clinical Trials - The ongoing Phase III TIGeR-PaC clinical trial is evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath in patients with locally advanced pancreatic cancer (LAPC) [3][7]. - RenovoRx is also supporting capital-efficient, investigator-initiated trials in borderline resectable and metastatic pancreatic cancer, which may enhance the clinical utility of the TAMP™ therapy platform [3]. Product Information - RenovoCath is designed for the isolation of blood flow and delivery of fluids to selected sites in the peripheral vascular system, and is indicated for temporary vessel occlusion in various applications [5][6]. - The combination product candidate (IAG) is currently under investigation and has not yet been approved for commercial sale, but has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8].